- Home
- HYNE vs KZIA Comparison
HYNE vs KZIA Comparison
Compare HYNE & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HYNE | KZIA |
|---|---|---|
| Founded | 2025 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 116.5M | 100.8M |
| IPO Year | N/A | 2002 |
Fundamental Metrics
Financial Performance| Metric | HYNE | KZIA |
|---|---|---|
| Price | $15.69 | $13.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $19.50 |
| AVG Volume (30 Days) | 15.9K | ★ 253.3K |
| Earning Date | 05-14-2026 | 06-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.56 | $3.24 |
| 52 Week High | $16.14 | $17.40 |
Technical Indicators
Market Signals| Indicator | HYNE | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 54.87 | 70.95 |
| Support Level | $15.49 | $5.85 |
| Resistance Level | N/A | $14.42 |
| Average True Range (ATR) | 0.23 | 1.18 |
| MACD | -0.06 | 0.10 |
| Stochastic Oscillator | 37.25 | 91.81 |
Price Performance
Historical ComparisonAbout HYNE Hoyne Bancorp Inc.
Hoyne Bancorp Inc is a holding company that conducts business mainly through its subsidiaries. It is a savings institution focused on serving customers' banking needs in the market area. The group offers Personal and Business banking services.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.